Mankind Pharma (BOM:543904) ROCE % : 25.49% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Mankind Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mankind Pharma's annualized ROCE % for the quarter that ended in Dec. 2023 was 25.49%.

Mankind Pharma ROCE % Historical Data

The historical data trend for Mankind Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mankind Pharma ROCE % Chart

Mankind Pharma Annual Data

Trend

Mar20

Mar21

Mar22

ROCE %

38.26

38.74

35.18

Mankind Pharma Quarterly Data
	Mar20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial					-	20.70	33.33	28.97	25.49

Mankind Pharma ROCE % Calculation

Mankind Pharma's annualized ROCE % for the fiscal year that ended in Mar. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2022 )		(A: Mar. 2021 )		(A: Mar. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2022 )		(A: Mar. 2021 )		(A: Mar. 2022 )
	=	20303.79	/	( ( (63726.32 - 13533.98)	+	(91477.4 - 26234.69) )	/ 2 )
	=	20303.79	/	( (50192.34	+	65242.71)	/ 2 )
	=	20303.79	/	57717.525
	=	35.18 %

Mankind Pharma's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	22860.584	/	( ( (110983.243 - 21284.117)	+	(0 - 0) )	/ 1 )
	=	22860.584	/	( ( 89699.126	+	0 )	/ 1 )
	=	22860.584	/	89699.126
	=	25.49 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Mankind Pharma (BOM:543904) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mankind Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Mankind Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mankind Pharma (BOM:543904) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mankind Pharma Ltd (BOM:543904) » Definitions » ROCE %

Traded in Other Exchanges

MANKIND:India

Address

262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020

Website

https://www.mankindpharma.com

Mankind Pharma Ltd is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News and Gas-O-Fast.

Mankind Pharma (BOM:543904) Headlines

No Headlines